Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

PURPOSE: A phase III trial comparing S-1 and docetaxel with S-1 alone as postoperative chemotherapy for pathologically Stage III gastric cancer was conducted and clarified the superiority of the doublet in terms of 3-year relapse-free survival as the primary endpoint (67.7% versus 57.4%, hazard rati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kodera, Yasuhiro, Yoshida, Kazuhiro, Kochi, Mitsugu, Sano, Takeshi, Ichikawa, Wataru, Kakeji, Yoshihiro, Sunakawa, Yu, Takeuchi, Masahiro, Fujii, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640480/
https://www.ncbi.nlm.nih.gov/pubmed/37548812
http://dx.doi.org/10.1007/s10120-023-01419-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640480/
https://www.ncbi.nlm.nih.gov/pubmed/37548812
http://dx.doi.org/10.1007/s10120-023-01419-9

Ejemplares similares